Click Holdings Limited (NASDAQ:CLIK) Short Interest Update

Click Holdings Limited (NASDAQ:CLIK) saw a significant decrease in short interest in July. As of July 15th, there was short interest totaling 1,939 shares, a decrease of 94.9% from the June 30th total of 37,691 shares. Based on an average daily volume of 56,286 shares, the short-interest ratio is presently 0.0 days. Approximately 0.2% of the shares of the stock are sold short.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on CLIK. Weiss Ratings reissued a “sell (d)” rating on shares of Click in a research note on Wednesday, June 24th. Wall Street Zen raised Click to a “hold” rating in a research note on Saturday, June 13th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Institutional Trading of Click

An institutional investor recently bought a new stake in Click stock. Renaissance Technologies LLC purchased a new stake in Click Holdings Limited (NASDAQ:CLIK) in the 1st quarter, according to its most recent filing with the SEC. The fund purchased 14,200 shares of the company’s stock, valued at approximately $25,000. Renaissance Technologies LLC owned about 1.23% of Click as of its most recent filing with the SEC.

Click Trading Up 1.9%

CLIK stock traded up $0.03 during trading on Friday, hitting $1.63. The stock had a trading volume of 45,626 shares, compared to its average volume of 373,797. The company’s 50 day moving average price is $1.57 and its two-hundred day moving average price is $2.70. Click has a 1-year low of $1.32 and a 1-year high of $14.40.

Click (NASDAQ:CLIK) last released its quarterly earnings results on Monday, May 11th. The company reported $0.10 earnings per share (EPS) for the quarter. The firm had revenue of $3.79 million for the quarter.

About Click

Click Therapeutics, Inc (NASDAQ: CLIK) is a clinical-stage digital therapeutics company developing software-based treatments for neurological, psychiatric and chronic diseases. Its platform delivers prescription digital therapies via mobile and web applications, combining evidence-based cognitive behavioral interventions, digital monitoring tools and patient engagement techniques. Click’s approach is designed to complement or extend traditional pharmacological and behavioral treatments for conditions such as major depressive disorder, insomnia and tobacco use disorder.

Founded in 2014, Click has progressed multiple programs through randomized controlled trials and regulatory review.